## **BAUSCH**-Health

## **News Releases** Register for email alerts. All Categories **Archive** Date 12/23/11 **Title** Valeant Pharmaceuticals Completes Syndication of Incremental Term Loans Download **PDF** 12/22/11 **Date Title** Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance **Download PDF** 12/22/11 **Date Title** Valeant Pharmaceuticals Completes Acquisition of iNova **Download PDF Date** 12/19/11 **Title** Valeant Pharmaceuticals Completes Acquisition of Dermik **Download PDF** 12/16/11 **Date Title**

Valeant Pharmaceuticals Proposes to Acquire ISTA Pharmaceuticals Inc. for \$6.50 Per Share in Cash **Download PDF Date** 12/16/11 **Title** Valeant Announces Successful Results From Phase III Onychomycosis Trials Download PDF 12/12/11 **Date Title** Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. **Download PDF** Date 12/12/11 **Title** Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik **Download PDF** 11/30/11 **Date Title** Valeant Pharmaceuticals to Syndicate Incremental Term Loans Download **PDF Date** 11/20/11 **Title** Valeant Pharmaceuticals Agrees to Acquire iNova **Download PDF** 11/10/11 **Date Title** Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer

Download	PDF	
Date	11/03/11	
Title		
Valeant Pharmaceuticals Repo	rts 2011 Third Quarter Financial Results	
Download	PDF	
Date	11/03/11	
Title		
Valeant Announces New \$1.5 B	illion Securities Repurchase Program	
Download	PDF	
Date	10/27/11	
Title		
Valeant Announces Take-Up of to Approve Its Privatization	Additional Afexa Shares and Special Meeting of Shareholders of Afexa	
Download	PDF	
Date	10/21/11	
Title		
Valeant Pharmaceuticals Succe	essfully Completes Refinancing of Senior Secured Credit Facilities	
Download	PDF	
Date	10/21/11	
Title		
Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011		
Download	PDF	
Date	10/18/11	
Title		
Valeant Announces Results of Friendly Offer for Afexa Life Sciences Inc.		
Download	PDF	

Date	09/30/11		
Title			
	Valeant Announces That Afexa Supports and Recommends Valeant's Increased Offer and Agrees to Certain Amendments to Support Agreement		
Download	PDF		
Date	09/28/11		
Title			
Valeant Pharmaceuticals	Announces Approval Of Colesevelam Hydrochloride In Canada		
Download	PDF		
Date	09/26/11		
Title			
Valeant Pharmaceuticals	Intends to Raise Offer for Afexa Life Sciences Inc. to \$0.85 per Share		
Download	PDF		
Date	09/26/11		
Title			
Valeant Pharmaceuticals	to Refinance Senior Secured Credit Facilities		
Download	PDF		
Date	09/20/11		
Title			
Valeant Pharmaceuticals Announces Second Request from the Federal Trade Commission in Connection with Pending Dermatology Acquisitions			
Download	PDF		
Date	09/09/11		
Title			
Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa			
Download	PDF Control of the co		

<b>Title</b> Valeant Pharmaceuticals to Present at Industry Conferences	
Download	PDF
Date	08/30/11
Title	
Valeant Pharmaceuticals Ar	nnounces All-Cash Offer to Acquire Afexa Life Sciences Inc.
Download	PDF
Date	08/29/11
Title	
Valeant Pharmaceuticals Ar Program	nnounces Increase to Monetary Limit Under Its Securities Repurchase
Download	PDF
Date	08/23/11
Title	
Valeant Pharmaceuticals Fil	es a Notice of Intention to Make a Normal Course Issuer Bid
Download	PDF
Date	08/19/11
Title	
Valeant Pharmaceuticals Co	ompletes Acquisition of Sanitas Group
Download	PDF
Date	08/18/11
Title	
Valeant Pharmaceuticals Ar Directors	nnounces Resignation of Michael Van Every From Valeant's Board of
Download	PDF
Date	08/04/11
Title	
Valeant Pharmaceuticals Re	eports 2011 Second Quarter Financial Results

Download	PDF
Date	08/03/11
Title	
Valeant Pharmaceuticals Ap	opoints Ronald Farmer to Fill Board Vacancy
Download	PDF
Date	08/03/11
Title	
Valeant Pharmaceuticals In	ternational, Inc.
Download	PDF
Date	07/25/11
Title	
Valeant Pharmaceuticals Ar	nnounces Approval of Sublinox® in Canada
Download	PDF
Date	07/20/11
Title	
Valeant Pharmaceuticals to	Announce 2011 Second Quarter Results on August 4, 2011
Download	PDF
Date	07/19/11
Title	
Valeant Pharmaceuticals Ar	nnounces Distribution Agreement for Zuacta(TM) in Canada
Download	PDF
Date	07/15/11
Title	
Valeant Pharmaceuticals Aç	grees to Acquire Ortho Dermatologics
Download	PDF
Date	07/11/11
	Page

## **Title** Valeant Pharmaceuticals Agrees to Acquire Dermik **Download PDF** 06/30/11 **Date Title** Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese(TM) **Download PDF** 06/13/11 **Date Title** Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga(TM) (ezogabine) **Download PDF** 05/24/11 **Date Title** Valeant Pharmaceuticals Agrees to Acquire Sanitas Group for Approximately EUR314 Million in Cash **Download PDF** 05/16/11 **Date Title** Kinerase® Introduces "Change Your Skin, Change Your Life" Charity Campaign **Download PDF** 05/11/11 **Date Title** Valeant Pharmaceuticals to Webcast 2011 Annual Meeting of Shareholders Download **PDF** 05/09/11 **Date Title** Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results

Title  Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction  Download  PDF  Date  04/29/11  Title  Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011  Download  PDF  Date  04/21/11  Title  Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download  PDF  Date  04/21/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download  PDF  Date  04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date  04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF  Date  04/18/11	Download	PDF
Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction  Download  PDF  Date 04/29/11  Title  Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011  Download PDF  Date 04/21/11  Title  Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download PDF  Date 04/21/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download PDF  Date 04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Date	05/02/11
Download  PDF  Date 04/29/11 Title  Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011  Download PDF  Date 04/21/11 Title  Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download PDF  Date 04/21/11 Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download PDF  Date 04/20/11 Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11 Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11 Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Title	
Date 04/29/11  Title  Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011  Download PDF  Date 04/21/11  Title  Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download PDF  Date 04/21/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download PDF  Date 04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Valeant Pharmaceutic	als Congratulates Teva and Cephalon on Their Transaction
Title Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011  Download  PDF  Date 04/21/11  Title Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download  PDF  Date 04/21/11  Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download  PDF  Date 04/20/11  Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date 04/18/11  Title Regulatory Update - CSK and Valeant Respond to FDA on ezogabine  Download  PDF	Download	PDF
Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011  Date 04/21/11  Title Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download PDF  Date 04/21/11  Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter Download PDF  Date 04/20/11  Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title Regulatory Update - GSK and Valeant Respond to FDA on ezogabine Download PDF	Date	04/29/11
Date 04/21/11  Title Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download PDF  Date 04/21/11  Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter Download PDF  Date 04/20/11  Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Title	
Date 04/21/11  Title Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download PDF  Date 04/21/11  Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download PDF  Date 04/20/11  Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title Regulatory Update - CSK and Valeant Respond to FDA on ezogabine  Download PDF	Valeant Pharmaceutic	als to Announce 2011 First Quarter Results on May 9, 2011
Title Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders  Download  PDF  Date  04/21/11  Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter Download  PDF  Date  04/20/11  Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date  04/18/11  Title Regulatory Update - GSK and Valeant Respond to FDA on ezogabine Download  PDF	Download	PDF
Download  PDF  Date 04/21/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download  PDF  Date 04/20/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download  PDF  Date 04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Date	04/21/11
Download  Date  O4/21/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download  PDF  Date  O4/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date  O4/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Title	
Date 04/21/11  Title  Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download PDF  Date 04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Valeant Pharmaceutic	als Announces Letter to Cephalon Stockholders
Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter  Download  PDF  Date  04/20/11  Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date  04/18/11  Title Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Download	PDF
Download  Date  O4/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date  O4/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Date	04/21/11
Download  PDF  Date 04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Title	
Date 04/20/11  Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download PDF	Valeant Pharmaceutic	als Responds to Cephalon Board's Letter
Title  Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Download	PDF
Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013  Download  PDF  Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Date	04/20/11
Download  Date  04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Title	
Date 04/18/11  Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Valeant Pharmaceutic	als Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
Title  Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Download	PDF
Regulatory Update - GSK and Valeant Respond to FDA on ezogabine  Download  PDF	Date	04/18/11
Download	Title	
	Regulatory Update - C	SK and Valeant Respond to FDA on ezogabine
Date 04/18/11	Download	PDF
	Date	04/18/11

## **Title** Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors Download **PDF Date** 04/11/11 **Title** Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders **Download PDF** 04/07/11 **Date** Title Meda to License Elidel to Valeant Pharmaceuticals Download **PDF** 04/05/11 **Date Title** Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC **Download PDF Date** 04/01/11 **Title** Promius Pharma and Valeant Form Collaboration to Market Cloderm(R) Cream in the United States Download **PDF** 03/29/11 **Date Title** Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for \$73 Per Share in Cash **Download PDF Date** 03/29/11 **Title** GSK and Valeant Receive European Authorisation for Trobalt (retigabine)

Download	PDF	
Date	03/22/11	
Title		
Valeant Pharmaceuticals Ex Chairman of the Board	tends Contract with J. Michael Pearson as CEO and Appoints Him as	
Download	PDF	
Date	03/11/11	
Title		
Valeant Pharmaceuticals Co	mpletes Acquisition of PharmaSwiss S.A.	
Download	PDF	
Date	03/03/11	
Title		
Valeant Announces Pricing	Valeant Announces Pricing of Senior Notes	
Download	PDF	
Date	03/01/11	
Title		
Valeant Launches Senior No	tes Offering	
Download	PDF	
Date	02/24/11	
Title		
Valeant Pharmaceuticals Reports 2010 Fourth Quarter Financial Results		
Download	PDF	
Date	02/16/11	
Title		
Valeant Pharmaceuticals to Present at RBC Capital Markets' 2011 Healthcare Conference		
Download	PDF	

	00/15/17
Date	02/15/11
Title	
Valeant Pharmaceuticals to Ar	nounce 2010 Fourth Quarter and Full Year Results on February 24, 2011
Download	PDF
Date	02/10/11
Title	
Valeant Pharmaceuticals Anno	ounces Acquisition of Cholestagel(R) in Canada
Download	PDF
Date	02/08/11
Title	
	ounces License Of ACZONE(R) (dapsone) Gel 5% In Canada
Download	PDF
Date	02/03/11
<b>Title</b> Valeant Launches Senior Notes	s Offering
	o onemig
Download	PDF
Date	02/03/11
	02,03,11
Title	Camian Nata
Valeant Announces Pricing of S	Senior Notes
Download	PDF
_	
Date	02/03/11
Title	
Valeant Pharmaceuticals to Acquire U.S. and Canadian Rights to Zovirax(R)	
Download	PDF
Date	02/01/11
Title	
Valeant Pharmaceuticals to Ac	quire PharmaSwiss S.A.

**Download PDF** 01/21/11 **Date Title** Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine) **Download PDF** Date 01/10/11 Title Valeant Pharmaceuticals to Present at J.P. Morgan 29th Annual Health Care Conference Download **PDF** 



**RSS FEED** 

LEGAL NOTICE **PRIVACY POLICY** 

**EMAIL ALERTS** 

<u>ir@bauschhealth.com</u>

**Investor Inquiries** 

877-281-6642

514-856-3855 (Canada)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

EMAIL PAGE

<u>Corporate.communications@bauschhealth.com</u>

908-569-3692

Media inquiries

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

